Initial characteristics and follow-up of ...
Document type :
Article dans une revue scientifique: Article original
PMID :
Permalink :
Title :
Initial characteristics and follow-up of patients with a diagnosis of angiotensin-converting enzyme inhibitor induced angioedema.
Author(s) :
Chepy, Aurelien [Auteur]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Veron, Marie [Auteur]
Centre de référence national des angiœdèmes [CREAK]
GAUTIER, Sophie [Auteur]
Lille Neurosciences & Cognition - U 1172 [LilNCog]
Farhat, Meryem-Maud [Auteur]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Pokeerbux, Ryadh [Auteur]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Venturelli, Giorgia [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Yelnik, Cecile [Auteur]
Facteurs de Risque et Déterminants Moléculaires des Maladies liées au Vieillissement - U 1167 [RID-AGE]
Dubucquoi, Sylvain [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Podevin, Céline [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Jendoubi, Manel [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Citerne, Isabelle [Auteur]
Service de médecine interne [Lille]
Baraffe, Jennifer [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Staumont, delphine [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Launay, David [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Sanges, Sébastien [Auteur]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Veron, Marie [Auteur]
Centre de référence national des angiœdèmes [CREAK]
GAUTIER, Sophie [Auteur]
Lille Neurosciences & Cognition - U 1172 [LilNCog]
Farhat, Meryem-Maud [Auteur]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Pokeerbux, Ryadh [Auteur]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Venturelli, Giorgia [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Yelnik, Cecile [Auteur]
Facteurs de Risque et Déterminants Moléculaires des Maladies liées au Vieillissement - U 1167 [RID-AGE]
Dubucquoi, Sylvain [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Podevin, Céline [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Jendoubi, Manel [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Citerne, Isabelle [Auteur]
Service de médecine interne [Lille]
Baraffe, Jennifer [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Staumont, delphine [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Launay, David [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Sanges, Sébastien [Auteur]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Journal title :
Allergy Asthma Proc
Abbreviated title :
Allergy Asthma Proc
Volume number :
43
Pages :
155-162
Publication date :
2022-03-24
ISSN :
1539-6304
English keyword(s) :
ACE inhibitors
Angioedema
Bradykinin-mediated angioedema
Chronic urticarial
Angioedema
Bradykinin-mediated angioedema
Chronic urticarial
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
Background:
A differential diagnosis between angiotensin-converting enzyme inhibitor (ACEi) angioedema (AE) and histaminergic AE (hAE) might be challenging. Follow-up data may help discriminate these conditions but are ...
Show more >Background: A differential diagnosis between angiotensin-converting enzyme inhibitor (ACEi) angioedema (AE) and histaminergic AE (hAE) might be challenging. Follow-up data may help discriminate these conditions but are scarcely reported. Objective: To report on the follow-up of patients with suspected ACEi-AE and to describe the baseline characteristics of AE attacks in patients with a diagnosis of ACEi-AE after follow-up. Methods: Sixty-four patients with suspected ACEi-AE (i.e., with exposure to ACEi before the first attack, no urticaria associated, and normal C1-inhibitor levels) and at least one follow-up visit were included. Data were retrospectively collected at baseline and during the follow-up. Results: After the follow-up, the diagnosis of ACEi-AE was probable in only 30 patients. The remaining patients were reclassified as having probable hAE (21 patients) or undetermined-mechanism AE (13 patients). Patients with ACEi-AE were mostly men (61%), with a median age of 64 years (interquartile range [IQR] ±17 years), with a highly variable delay from ACEi introduction (median: 23 months; interquartile range: 103 months). Attacks preferentially involved lips (50%), tongue (47%), and throat (30%). Interestingly, patients with probable ACEi-AE after a follow-up also frequently presented with a history of allergy and atopic conditions (20%), attacks with preferential evening onset (25%), and spontaneous resolution in < 24 hours (26%), which are usually considered as suggestive of hAE. ACEi-AE attacks responded to icatibant in 79% of the patients. Conclusion: Patients with probable ACEi-AE were mostly men with facial involvement. A third of the patients with an initial suspected diagnosis of ACEi-AE had a final diagnosis of probable hAE. Although a follow-up of all patients should be a standard of care, it is critical to the correct diagnosis in the case of suspected bradykinin-associated AE, which may actually be due to histamine.Show less >
Show more >Background: A differential diagnosis between angiotensin-converting enzyme inhibitor (ACEi) angioedema (AE) and histaminergic AE (hAE) might be challenging. Follow-up data may help discriminate these conditions but are scarcely reported. Objective: To report on the follow-up of patients with suspected ACEi-AE and to describe the baseline characteristics of AE attacks in patients with a diagnosis of ACEi-AE after follow-up. Methods: Sixty-four patients with suspected ACEi-AE (i.e., with exposure to ACEi before the first attack, no urticaria associated, and normal C1-inhibitor levels) and at least one follow-up visit were included. Data were retrospectively collected at baseline and during the follow-up. Results: After the follow-up, the diagnosis of ACEi-AE was probable in only 30 patients. The remaining patients were reclassified as having probable hAE (21 patients) or undetermined-mechanism AE (13 patients). Patients with ACEi-AE were mostly men (61%), with a median age of 64 years (interquartile range [IQR] ±17 years), with a highly variable delay from ACEi introduction (median: 23 months; interquartile range: 103 months). Attacks preferentially involved lips (50%), tongue (47%), and throat (30%). Interestingly, patients with probable ACEi-AE after a follow-up also frequently presented with a history of allergy and atopic conditions (20%), attacks with preferential evening onset (25%), and spontaneous resolution in < 24 hours (26%), which are usually considered as suggestive of hAE. ACEi-AE attacks responded to icatibant in 79% of the patients. Conclusion: Patients with probable ACEi-AE were mostly men with facial involvement. A third of the patients with an initial suspected diagnosis of ACEi-AE had a final diagnosis of probable hAE. Although a follow-up of all patients should be a standard of care, it is critical to the correct diagnosis in the case of suspected bradykinin-associated AE, which may actually be due to histamine.Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
Université de Lille
Inserm
CHU Lille
Inserm
CHU Lille
Collections :
Submission date :
2024-01-12T02:01:17Z
2024-03-04T11:03:28Z
2024-03-04T11:05:39Z
2024-03-04T11:03:28Z
2024-03-04T11:05:39Z